Merck

MK-3475-495

NCT03516981

JCP057

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PD-L1, GEP, TMB

Investigational

Product

Pembrolizumab (MK-3475)

Anti-PD1 antibody (i.v.)

Treatment Arms

o Experimental: GEP low TMB low: Pembrolizumab + Quavonlimab

o Experimental: GEP low TMB low: Pembrolizumab + MK-4280

o Experimental: GEP low TMB low: Pembrolizumab + Lenvatinib

o Experimental: GEP low TMB hi: Pembrolizumab + Quavonlimab

o Experimental: GEP low TMB hi: Pembrolizumab + MK-4280

o Experimental: GEP low TMB hi: Pembrolizumab + Lenvatinib

o Experimental: GEP hi TMB low: Pembrolizumab + Quavonlimab

o Experimental: GEP hi TMB low: Pembrolizumab + MK-4280

o Experimental: GEP hi TMB low: Pembrolizumab + Lenvatinib

o Experimental: GEP hi TMB hi: Pembrolizumab + Guavonlimab

o Experimental: GEP hi TMB hi: Pembrolizumab + MK-4280

o Experimental: GEP hi TMB hi: Pembrolizumab + Lenvatinib